Pacira BioSciences, Inc.
Lauren Riker (Senior Vice President, Finance) sells PCRX shares
About this filing
Pacira BioSciences, Inc. (PCRX) filed Form 4 (insider transaction) with the SEC on Oct 9, 2026. Form 4 reports a company insider’s trades in the company’s shares.
Key facts
- Insider
- Lauren Riker · Senior Vice President, Finance
Rule 10b5-1 plan · adopted Mar 12, 2026
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Oct 8, 2026 | M · exercise or conversion of a derivativeFootnotes F1 | +6,000 | $32.35 | $194,100.00 | 68,284.242 | Direct |
| Oct 8, 2026 | S · open-market saleFootnotes F1 | −6,000 | $36.32 | $217,920.00 | 62,284.242 | Direct |
| Oct 8, 2026 | M · exercise or conversion of a derivativeStock Option (Right to Buy)Footnotes F1, F2 | −6,000 | $0.00 | $0.00 | 0 | Direct |
Footnotes
- F1 The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026.
- F2 The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years.
More PCRX filings
- SC 13G/A
Filed Oct 30, 2026
- SC 14D9
Filed Oct 30, 2026
- SC 13D/A
Filed Oct 13, 2026
- SC14D9C
Filed Oct 8, 2026
- 144
Filed Oct 8, 2026
- 8-K
Filed Oct 8, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.